---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-117728"
form_type: "8-K"
ticker: "NNVC"
cik: "0001379006"
company_name: "NANOVIRICIDES, INC."
filed_at: "2021-09-21T23:59:59+00:00"
generated_at: "2026-06-29T02:16:30.453957+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NanoViricides reports NV-CoV-2-R shows nearly 2x intact remdesivir in plasma vs standard in rat study

## Summary
- Almost double intact remdesivir in plasma on day 1 of dosing with NV-CoV-2-R vs standard remdesivir.
- After fifth dose (day 7), circulating remdesivir 75% greater in NV-CoV-2-R group.
- NV-CoV-2-R combines nanoviricides platform attack on virus outside cells with remdesivir inside cells.
- Company expects improved pan-coronavirus activity retaining effectiveness against emerging variants.
- Draft data inadvertently published; final press release expected by September 28, 2021.

## SEC filing metadata
- accession: 0001104659-21-117728
- form_type: 8-K
- ticker: NNVC
- cik: 0001379006
- company_name: NANOVIRICIDES, INC.
- filed_at: 2021-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1379006/000110465921117728/0001104659-21-117728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1379006/000110465921117728/tm2128140d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-117728
- JSON: https://secwatch.observer/filing/0001104659-21-117728.json
- Plain text: https://secwatch.observer/filing/0001104659-21-117728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.